Gardiquimod

Research use only, not for human use.

Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells.

Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10?μM, Gardiquimod specifically activates TLR7.(In Vitro):Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis.(In Vivo):Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells.

Gardiquimod (6-60?μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase.

Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells. Animal Model:Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)Dosage:1 mg/kg per mouse Administration:i.p.; daily for 7 days Result:Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.

——

Immunology/Inflammation

TLR

Estrogen Receptor/ERR| Human Endogenous Metabolite

——

——

1020412-43-4

313.405

C17H23N5O

>98% (HPLC)

In Vitro:?DMF : ≥ 20 mg/mL (63.82 mM)DM)

CCNCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O

——

(-20℃)

With Ice Pack

≥ 2 years